Meeting the primary endpoint in a study typically indicates positive outcomes for the drug or treatment being tested, which can lead to increased investor confidence and potential future revenue streams. This news directly impacts Cellectar Biosciences and is likely to be viewed positively by investors, potentially leading to a short-term increase in stock price.